US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
HUP0600342A3
(en)
*
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
WO2003059934A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20070161087A1
(en)
*
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
CN1802386B
(zh)
*
|
2003-06-12 |
2010-12-15 |
伊莱利利公司 |
Glp-1类似物融合蛋白质
|
HUE027902T2
(en)
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
KR100879662B1
(ko)
*
|
2004-12-22 |
2009-01-20 |
일라이 릴리 앤드 캄파니 |
Glp-1 유사체 융합 단백질 제제
|
PL1881850T3
(pl)
*
|
2005-05-13 |
2011-03-31 |
Lilly Co Eli |
Pegylowane związki GLP-1
|
CA2658673A1
(en)
*
|
2005-07-27 |
2008-02-01 |
Gerald J. Prud'homme |
Composition and method for prevention and treatment of type i and type ii diabetes
|
CN101277722A
(zh)
|
2005-08-06 |
2008-10-01 |
王庆华 |
用于预防和治疗ⅰ型糖尿病的组合物及方法
|
SI1767545T1
(sl)
*
|
2005-09-22 |
2010-03-31 |
Biocompatibles Uk Ltd |
GLP Glukagonu podobni peptidi fuzijski polipeptidi s povečano rezistenco na peptidazo
|
US20070212355A1
(en)
*
|
2005-10-24 |
2007-09-13 |
Baker Audrey E |
GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses
|
SI1965823T1
(sl)
|
2005-11-04 |
2016-09-30 |
Glaxosmithkline Llc Corporation Service Company |
Postopki za dajanje hipoglikemičnih sredstev
|
WO2007056362A2
(en)
*
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
JP2009534423A
(ja)
|
2006-04-20 |
2009-09-24 |
アムジェン インコーポレイテッド |
Glp−1化合物
|
JP5290177B2
(ja)
*
|
2006-08-31 |
2013-09-18 |
セントカー・インコーポレーテツド |
Glp−2ミメティボディ、ポリペプチド、組成物、方法および用途
|
US20110039776A1
(en)
*
|
2006-09-06 |
2011-02-17 |
Ashutosh Chilkoti |
Fusion peptide therapeutic compositions
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
US8754194B2
(en)
|
2006-12-22 |
2014-06-17 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
EP2124974B1
(en)
*
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
EP2109457B1
(en)
|
2007-02-12 |
2016-01-06 |
CSL Behring GmbH |
Therapeutic application of kazal-type serine protease inhibitors
|
CN101790538B
(zh)
|
2007-02-15 |
2014-07-30 |
印第安纳大学研究与科技公司 |
胰高血糖素/glp-1受体共激动剂
|
CN101951940A
(zh)
*
|
2007-03-15 |
2011-01-19 |
比奥根艾迪克Ma公司 |
自身免疫病的治疗
|
AU2008264750C1
(en)
*
|
2007-06-19 |
2013-01-10 |
Glytech, Inc. |
GLP-1 peptide having sugar chain attached thereto
|
WO2009020802A2
(en)
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
EP2031064A1
(de)
*
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
JP5669582B2
(ja)
|
2007-10-30 |
2015-02-12 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト
|
JP5771005B2
(ja)
*
|
2007-10-30 |
2015-08-26 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
EP2249853A4
(en)
*
|
2008-01-30 |
2012-12-26 |
Univ Indiana Res & Tech Corp |
PEPTIDE PRODRUGS BASED ON ESTERS
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
PE20100056A1
(es)
*
|
2008-06-17 |
2010-01-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon como agonistas gip
|
EP2300037B1
(en)
|
2008-06-17 |
2016-03-30 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
CN104447980A
(zh)
*
|
2008-06-17 |
2015-03-25 |
印第安纳大学研究及科技有限公司 |
在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
|
EP2291523B1
(en)
|
2008-06-24 |
2014-12-17 |
CSL Behring GmbH |
Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
|
EP2307038A4
(en)
|
2008-06-27 |
2013-03-27 |
Univ Duke |
THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
|
SG195542A1
(en)
|
2008-10-10 |
2013-12-30 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
RU2550696C2
(ru)
|
2008-12-19 |
2015-05-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Основанные на амидах пролекарства пептидов глюкагонового надсемейства
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
CA2760674A1
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
TWI560197B
(en)
|
2009-05-05 |
2016-12-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
SG176858A1
(en)
|
2009-06-16 |
2012-02-28 |
Univ Indiana Res & Tech Corp |
Gip receptor-active glucagon compounds
|
WO2010148142A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
WO2011043530A1
(ko)
*
|
2009-10-09 |
2011-04-14 |
(주)알테오젠 |
Glp-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
|
CA2782814A1
(en)
*
|
2009-12-02 |
2011-06-09 |
Amgen Inc. |
Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
|
UA109888C2
(uk)
*
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
US8551946B2
(en)
|
2010-01-27 |
2013-10-08 |
Indiana University Research And Technology Corporation |
Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
AU2011239689A1
(en)
|
2010-04-15 |
2012-11-08 |
Amgen Inc. |
Human FGF receptor and beta-Klotho binding proteins
|
CA2793715A1
(en)
|
2010-04-30 |
2011-11-03 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
|
CN103179976A
(zh)
|
2010-05-13 |
2013-06-26 |
印第安纳大学研究及科技有限公司 |
呈现g蛋白偶联受体活性的胰高血糖素超家族肽
|
CN103079587B
(zh)
|
2010-05-13 |
2016-05-11 |
印第安纳大学研究及科技有限公司 |
呈现核激素受体活性的胰高血糖素超家族肽
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
CA2796894A1
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
JP6069198B2
(ja)
*
|
2010-07-20 |
2017-02-01 |
ノヴォ ノルディスク アー/エス |
N末端が修飾されたfgf21化合物
|
ES2713952T3
(es)
|
2010-12-22 |
2019-05-24 |
Univ Indiana Res & Tech Corp |
Análogos de glucagón que muestran actividad de receptor de GIP
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
WO2012120128A1
(en)
|
2011-03-09 |
2012-09-13 |
Csl Behring Gmbh |
Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
|
EP2497489A1
(en)
|
2011-03-09 |
2012-09-12 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
|
PT2691417T
(pt)
|
2011-03-29 |
2018-10-31 |
Roche Glycart Ag |
Variantes de fc de anticorpos
|
GEP20176629B
(en)
|
2011-06-22 |
2017-02-27 |
Indiana Unversity Research And Tech Corporation |
Glucagon/glp-1 receptor co-agonists
|
JP6184404B2
(ja)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン/glp−1レセプターコアゴニスト
|
CN103687878B
(zh)
|
2011-07-22 |
2018-01-09 |
德国杰特贝林生物制品有限公司 |
抑制性的抗因子xii/xiia单克隆抗体及其用途
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
KR20130049671A
(ko)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
생리활성 폴리펩타이드 결합체 제조 방법
|
KR20140097151A
(ko)
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
PL2814502T3
(pl)
|
2012-02-15 |
2018-02-28 |
Csl Behring Gmbh |
Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
|
TWI599575B
(zh)
|
2012-06-21 |
2017-09-21 |
印第安納大學科技研究公司 |
表現gip受體活性之胰高血糖素類似物
|
ES2896493T3
(es)
|
2012-07-13 |
2022-02-24 |
Roche Glycart Ag |
Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
KR102426488B1
(ko)
*
|
2012-09-12 |
2022-07-28 |
젠자임 코포레이션 |
변경된 당화 및 감소된 효과기 기능을 갖는 fc 함유 폴리펩티드
|
JP6026002B2
(ja)
|
2012-11-27 |
2016-11-16 |
アルテオジェン インコーポレイテッド |
タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物
|
LT3115372T
(lt)
|
2012-11-27 |
2019-06-25 |
Biomarin Pharmaceutical Inc. |
Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas
|
AU2014224599B2
(en)
|
2013-03-08 |
2018-11-08 |
Csl Behring Gmbh |
Treatment and prevention of remote ischemia-reperfusion injury
|
RU2708314C2
(ru)
|
2013-03-11 |
2019-12-05 |
Джензим Корпорейшн |
Гипергликозилированные связывающие полипептиды
|
RU2678134C2
(ru)
|
2013-03-14 |
2019-01-23 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты инсулин-инкретин
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
JP2017501968A
(ja)
|
2013-06-28 |
2017-01-19 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
第xii因子インヒビターおよびc1−インヒビターを使用する組合せ療法
|
CN103408669B
(zh)
|
2013-08-01 |
2016-01-20 |
江苏泰康生物医药有限公司 |
Glp-1类似物融合蛋白,及其制备方法和用途
|
CN104592381A
(zh)
*
|
2013-10-31 |
2015-05-06 |
江苏万邦生化医药股份有限公司 |
一种利拉鲁肽中间体多肽的制备方法
|
WO2015138278A1
(en)
|
2014-03-11 |
2015-09-17 |
Novartis Ag |
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
|
SG10201808158UA
(en)
|
2014-03-19 |
2018-10-30 |
Genzyme Corp |
Site-specific glycoengineering of targeting moieties
|
US20170128589A1
(en)
*
|
2014-03-31 |
2017-05-11 |
Hanmi Pharm. Co., Ltd. |
Method for improving solubility of protein and peptide by using immunoglogulin fc fragment linkage
|
US20170114119A1
(en)
|
2014-06-18 |
2017-04-27 |
Csl Behring Gmbh |
Therapy using a factor xii inhibitor in a neurotraumatic disorder
|
EP3164150B1
(en)
|
2014-07-02 |
2020-11-04 |
CSL Behring Lengnau AG |
Modified von willebrand factor
|
JP6768633B2
(ja)
|
2014-07-21 |
2020-10-14 |
デリニア, インコーポレイテッド |
自己免疫疾患を治療するために調節性t細胞を選択的に活性化する分子
|
CN113234138A
(zh)
|
2014-08-11 |
2021-08-10 |
德里尼亚公司 |
选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
|
US10232020B2
(en)
|
2014-09-24 |
2019-03-19 |
Indiana University Research And Technology Corporation |
Incretin-insulin conjugates
|
CN104293834B
(zh)
*
|
2014-10-11 |
2018-03-23 |
上海兴迪金生物技术有限公司 |
GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
|
TWI681966B
(zh)
|
2014-12-23 |
2020-01-11 |
丹麥商諾佛 儂迪克股份有限公司 |
Fgf21衍生物及其用途
|
KR101825048B1
(ko)
*
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
|
US10851144B2
(en)
|
2015-04-10 |
2020-12-01 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
AR105616A1
(es)
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
Proteínas de fusión
|
EP3298036B1
(en)
|
2015-05-22 |
2022-04-06 |
CSL Behring Lengnau AG |
Methods for preparing modified von willebrand factor
|
RU2017145014A
(ru)
|
2015-05-22 |
2019-06-24 |
Цсл Беринг Ленгнау Аг |
Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
KR102668200B1
(ko)
|
2015-10-28 |
2024-05-23 |
주식회사유한양행 |
지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
|
KR102670157B1
(ko)
|
2015-10-28 |
2024-05-29 |
주식회사유한양행 |
이중 작용 단백질 및 이를 포함하는 약학적 조성물
|
CR20180378A
(es)
|
2015-12-23 |
2018-12-06 |
Amgen Inc |
Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
|
EP3184149A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Soluble glycoprotein v for treating thrombotic diseases
|
RU2018128613A
(ru)
|
2016-01-07 |
2020-02-07 |
Цсл Беринг Ленгнау Аг |
Мутированный фактор фон виллебранда
|
MX2018008337A
(es)
|
2016-01-07 |
2018-09-17 |
CSL Behring Lengnau AG |
Factor de von willebrand truncado mutado.
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
EP3440107A4
(en)
|
2016-04-06 |
2020-02-19 |
CSL Limited |
METHOD FOR TREATING ATHEROSCLEROSIS
|
KR20180135458A
(ko)
|
2016-04-26 |
2018-12-20 |
알.피.쉐러 테크놀러지즈 엘엘씨 |
항체 컨쥬게이트 및 이의 제조 및 이용 방법
|
US10336812B2
(en)
*
|
2016-05-10 |
2019-07-02 |
Janssen Biotech, Inc. |
GDF15 fusion proteins and uses thereof
|
EP3502143A4
(en)
|
2016-08-19 |
2020-07-15 |
Ampsource Biopharma Shanghai Inc. |
BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
|
CN106317226B
(zh)
|
2016-08-19 |
2017-09-05 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技(上海)有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
AU2017359172A1
(en)
|
2016-11-08 |
2019-05-16 |
Delinia, Inc. |
IL-2 variants for the treatment of autoimmune diseases
|
CN110121355B
(zh)
|
2016-11-10 |
2023-09-12 |
株式会社柳韩洋行 |
用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
|
EP3538133B1
(en)
|
2016-11-11 |
2021-02-17 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
TW201828974A
(zh)
|
2016-11-11 |
2018-08-16 |
瑞士商Csl貝林重組技能公司 |
用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類
|
EP3351262A1
(en)
|
2016-12-30 |
2018-07-25 |
Istanbul Universitesi Rektorlugu |
Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
EP3612637A4
(en)
|
2017-04-21 |
2021-01-27 |
Yuhan Corporation |
DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES
|
EP4279925A3
(en)
|
2017-06-01 |
2024-01-24 |
Eli Lilly and Company |
Dulaglutide for the treatment of chronic kidney disease
|
BR112019026743A2
(pt)
|
2017-06-22 |
2020-06-30 |
CSL Behring Lengnau AG |
modulação da imunogenicidade de fviii através de vwf truncado
|
MX2020002977A
(es)
|
2017-09-22 |
2020-11-06 |
Regeneron Pharma |
Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
|
BR112020007817A2
(pt)
|
2017-11-21 |
2020-10-06 |
Eli Lilly And Company |
método de uso e composições contendo dulaglutido
|
WO2019119673A1
(zh)
|
2017-12-19 |
2019-06-27 |
北京吉源生物科技有限公司 |
一种双基因修饰的干细胞及其用途
|
US11491235B2
(en)
|
2017-12-22 |
2022-11-08 |
Kb Biomed Inc. |
Oral gene carrier and use thereof
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
AU2019218147B2
(en)
|
2018-02-08 |
2023-06-08 |
Sunshine Lake Pharma Co., Ltd. |
FGF21 variant, fusion protein and application thereof
|
KR20200135618A
(ko)
|
2019-05-23 |
2020-12-03 |
㈜ 디앤디파마텍 |
폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
|
JP2021530533A
(ja)
|
2018-07-19 |
2021-11-11 |
ディーアンドディー ファーマテック インコーポレイテッド |
ポリペプチドを含む医薬組成物
|
CN110878127B
(zh)
|
2018-09-06 |
2022-06-28 |
浙江柏拉阿图医药科技有限公司 |
长效重组GLP1-Fc-CD47蛋白及其制备和用途
|
CN111234000B
(zh)
*
|
2018-11-28 |
2023-05-26 |
鲁南制药集团股份有限公司 |
艾塞纳肽类似物
|
CN111269312B
(zh)
*
|
2018-12-04 |
2023-05-09 |
鲁南制药集团股份有限公司 |
一种异源融合蛋白质
|
CN109836486B
(zh)
*
|
2019-01-30 |
2020-09-08 |
北京双因生物科技有限公司 |
成纤维生长因子21变体、其融合蛋白及其用途
|
CA3123325A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Sunshine Lake Pharma Co., Ltd. |
A polypeptide molecule and application thereof
|
AU2020233876A1
(en)
|
2019-03-08 |
2021-09-23 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
JP2022525883A
(ja)
|
2019-03-15 |
2022-05-20 |
イーライ リリー アンド カンパニー |
保存製剤
|
CA3056663C
(en)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
|
CA3138650A1
(en)
|
2019-05-17 |
2020-11-26 |
Universitaet Zuerich |
Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
|
CN114072420B
(zh)
|
2019-07-04 |
2024-06-11 |
康诺贝林伦瑙有限公司 |
用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
|
CN114555792A
(zh)
|
2019-10-15 |
2022-05-27 |
伊莱利利公司 |
重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
|
WO2021094344A1
(en)
|
2019-11-11 |
2021-05-20 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
WO2021139744A1
(en)
|
2020-01-11 |
2021-07-15 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Conjugates of fusion proteins of glp-1 and fgf21
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
BR112023003310A2
(pt)
|
2020-08-24 |
2023-05-02 |
Univ Pennsylvania |
Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas
|
CN114106194B
(zh)
*
|
2020-08-31 |
2024-01-16 |
中国科学院天津工业生物技术研究所 |
一种用于治疗糖尿病和/或肥胖症的融合蛋白
|
EP4247416A1
(en)
|
2020-11-20 |
2023-09-27 |
CSL Behring GmbH |
Method for treating antibody-mediated rejection
|
CN114685644A
(zh)
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
一种人glp-1多肽变体及其应用
|
WO2022162218A1
(en)
|
2021-02-01 |
2022-08-04 |
Csl Behring Ag |
Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
|
EP4334342A1
(en)
|
2021-05-07 |
2024-03-13 |
CSL Behring AG |
Expression system for producing a recombinant haptoglobin (hp) beta chain
|
JP2024524530A
(ja)
|
2021-07-06 |
2024-07-05 |
スジョウ・アルファマブ・カンパニー・リミテッド |
融合タンパク質及びその使用
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|
CN114774496B
(zh)
*
|
2022-06-21 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
一种高密度发酵制备glp-1类似物的方法
|
WO2024047219A1
(en)
|
2022-09-02 |
2024-03-07 |
Csl Behring Ag |
Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
|
US20240199728A1
(en)
|
2022-09-21 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating obesity, diabetes, and liver dysfunction
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
WO2024132147A1
(en)
|
2022-12-22 |
2024-06-27 |
Lifearc |
Galanin-2 receptor agonists
|